Cargando…

545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017

BACKGROUND: Carbapenem-nonsusceptible Acinetobacter spp. (CNAB) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are recognized causes of severe and difficult to treat healthcare-associated infections. This study estimated and compared the incidence of CNAB and CRPA among patients admitted to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazakova, Sophia, Baggs, James, Wolford, Hannah, Olubajo, Babatunde, Hatfield, Kelly M, See, Isaac, Bulens, Sandra N, Reddy, Sujan, Jernigan, John A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810889/
http://dx.doi.org/10.1093/ofid/ofz360.614
_version_ 1783462347201839104
author Kazakova, Sophia
Baggs, James
Wolford, Hannah
Olubajo, Babatunde
Hatfield, Kelly M
See, Isaac
Bulens, Sandra N
Reddy, Sujan
Jernigan, John A
author_facet Kazakova, Sophia
Baggs, James
Wolford, Hannah
Olubajo, Babatunde
Hatfield, Kelly M
See, Isaac
Bulens, Sandra N
Reddy, Sujan
Jernigan, John A
author_sort Kazakova, Sophia
collection PubMed
description BACKGROUND: Carbapenem-nonsusceptible Acinetobacter spp. (CNAB) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are recognized causes of severe and difficult to treat healthcare-associated infections. This study estimated and compared the incidence of CNAB and CRPA among patients admitted to US acute care hospitals in 2012–2017. METHODS: We measured the incidence of positive clinical cultures from inpatient encounters in a cohort of over 300 hospitals submitting data to the Premier Healthcare Database and Cerner Health Facts in 2012–2017. We included clinical cultures from any body site yielding Acinetobacter spp./P. aeruginosa non-susceptible/resistant to imipenem, meropenem, or doripenem. Cultures collected on days 1–3 of hospitalization were considered community-onset (CO) and cultures from later were hospital-onset (HO). Duplicate isolates identified within 14 days of an incident culture and surveillance cultures were excluded. For each year, a raking procedure generated weights to extrapolate the sample estimate to match the American Hospital Association distributions based on US census division, hospital bed capacity, teaching status, and urban designation. We compared estimated rates in 2017 vs. 2012 using weighted multivariable logistic regression adjusting for hospital characteristics and hospital-level clustering. RESULTS: In 2017, the estimated rates of HO and CO CNAB rates were 0.77 and 1.39/10,000 discharges, and HO and CO CRPA rates were 3.14 and 6.57, respectively. Compared with 2017, rates of HO CNAB decreased 49% (Odds Ratio (OR) 0.51; 95% CI: 0.34–0.75) and rates of CO CNAB decreased 29% (OR 0.71; 95% CI: 0.54–0.92). For CRPA, the incidence of HO decreased (OR 0.66; CI: 0.49–0.88) with no change in CO rates (OR 0.93; CI: 0.79–1.11). Assessment of cultures from sterile sites alone showed similar results, but they did not reach statistical significance, Figure 1. CONCLUSION: We estimate significant national decreases in the rates of HO and CO CNAB, and HO CRPA. Risk factors and effective interventions to reduce CO CRPA might differ from CNAB and HO CRPA. Additional prevention strategies are needed to address CO CRPA. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810889
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68108892019-10-28 545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017 Kazakova, Sophia Baggs, James Wolford, Hannah Olubajo, Babatunde Hatfield, Kelly M See, Isaac Bulens, Sandra N Reddy, Sujan Jernigan, John A Open Forum Infect Dis Abstracts BACKGROUND: Carbapenem-nonsusceptible Acinetobacter spp. (CNAB) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are recognized causes of severe and difficult to treat healthcare-associated infections. This study estimated and compared the incidence of CNAB and CRPA among patients admitted to US acute care hospitals in 2012–2017. METHODS: We measured the incidence of positive clinical cultures from inpatient encounters in a cohort of over 300 hospitals submitting data to the Premier Healthcare Database and Cerner Health Facts in 2012–2017. We included clinical cultures from any body site yielding Acinetobacter spp./P. aeruginosa non-susceptible/resistant to imipenem, meropenem, or doripenem. Cultures collected on days 1–3 of hospitalization were considered community-onset (CO) and cultures from later were hospital-onset (HO). Duplicate isolates identified within 14 days of an incident culture and surveillance cultures were excluded. For each year, a raking procedure generated weights to extrapolate the sample estimate to match the American Hospital Association distributions based on US census division, hospital bed capacity, teaching status, and urban designation. We compared estimated rates in 2017 vs. 2012 using weighted multivariable logistic regression adjusting for hospital characteristics and hospital-level clustering. RESULTS: In 2017, the estimated rates of HO and CO CNAB rates were 0.77 and 1.39/10,000 discharges, and HO and CO CRPA rates were 3.14 and 6.57, respectively. Compared with 2017, rates of HO CNAB decreased 49% (Odds Ratio (OR) 0.51; 95% CI: 0.34–0.75) and rates of CO CNAB decreased 29% (OR 0.71; 95% CI: 0.54–0.92). For CRPA, the incidence of HO decreased (OR 0.66; CI: 0.49–0.88) with no change in CO rates (OR 0.93; CI: 0.79–1.11). Assessment of cultures from sterile sites alone showed similar results, but they did not reach statistical significance, Figure 1. CONCLUSION: We estimate significant national decreases in the rates of HO and CO CNAB, and HO CRPA. Risk factors and effective interventions to reduce CO CRPA might differ from CNAB and HO CRPA. Additional prevention strategies are needed to address CO CRPA. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810889/ http://dx.doi.org/10.1093/ofid/ofz360.614 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kazakova, Sophia
Baggs, James
Wolford, Hannah
Olubajo, Babatunde
Hatfield, Kelly M
See, Isaac
Bulens, Sandra N
Reddy, Sujan
Jernigan, John A
545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017
title 545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017
title_full 545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017
title_fullStr 545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017
title_full_unstemmed 545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017
title_short 545. Incidence of Carbapenem Non-Susceptible Acinetobacter spp. and Carbapenem-Resistant Pseudomonas aeruginosa Clinical Cultures among Patients in US Acute Care Hospitals, 2012–2017
title_sort 545. incidence of carbapenem non-susceptible acinetobacter spp. and carbapenem-resistant pseudomonas aeruginosa clinical cultures among patients in us acute care hospitals, 2012–2017
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810889/
http://dx.doi.org/10.1093/ofid/ofz360.614
work_keys_str_mv AT kazakovasophia 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT baggsjames 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT wolfordhannah 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT olubajobabatunde 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT hatfieldkellym 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT seeisaac 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT bulenssandran 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT reddysujan 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017
AT jerniganjohna 545incidenceofcarbapenemnonsusceptibleacinetobactersppandcarbapenemresistantpseudomonasaeruginosaclinicalculturesamongpatientsinusacutecarehospitals20122017